Indication
Lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease in adult patients that are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers.
Medicine details
- Medicine name:
- lecanemab (Leqembi)
- SMC ID:
- SMC2700
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Publication due date:
- 10 February 2025
- SMC meeting date:
- 07 January 2025
- Patient group submission deadline:
- 02 December 2024